Randy Osborne
Odyssey Therapeutics Inc. launched with a whopping $218 million series A round, the year’s second-largest, to fuel work by almost 100 employees recruited in the past few months, mostly from big pharma firms.
Media
Frank Vinluan
At the start of 2021, serial biotech entrepreneur Gary Glick revealed a mega-round of financing for his new precision oncology startup. Now he’s back at it again, bringing along some familiar investors who have joined forces to raise even more money—$218 million—for yet another startup he founded, Odyssey Therapeutics. That biotech is setting out with programs already in development in cancer and immunology.
Kyle LaHucik
Nine months young and five months since hiring its first employee, Odyssey Therapeutics has secured $218 million to bankroll seven programs across cancer and inflammation. Its first study in humans will be in late 2023 or early 2024.
Max Gelman
Gary Glick is back at it again, founding yet another biotech company. And by the sheer size of its first raise, this may be the biggest one yet.
Ryan Cross
Odyssey Therapeutics isn’t Gary Glick’s first biotech start-up. Or his second. It’s his fifth. The serial entrepreneur has earned a reputation for launching one company after another to develop small-molecule drugs for cancer and immune diseases. Many of those firms, working on popular targets including STING and the NLRP3 inflammasome, were quickly snatched up by larger firms. But Odyssey could be his biggest venture yet.
Rowan Walrath
It wasn’t long ago that serial biotech entrepreneur Gary Glick said he was settling down. Glick, the former CEO of IFM Therapeutics, had launched precision-medicine startup Scorpion Therapeutics in 2020 when he told the Business Journal: “It will be the last company that I start.”